Biogen Inc AR (BIIBm)

Buenos Aires
Currency in ARS
12,100.00
-150.00(-1.22%)
Closed·
BIIBm Scorecard
Full Analysis
Trading at a low P/E ratio relative to near-term earnings growth
Unusual trading volume
Fair Value
Day's Range
12,050.0012,375.00
52 wk Range
9,930.0028,500.00
Key Statistics
Edit
Bid/Ask
12,050.00 / 17,700.00
Prev. Close
12,250
Open
12,250
Day's Range
12,050-12,375
52 wk Range
9,930-28,500
Volume
18.77K
Average Volume (3m)
1.31K
1-Year Change
-47.58%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
BIIBm Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Valuation implies a strong free cash flow yield

Biogen Inc AR News & Analysis

Show more

Biogen AR Company Profile

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS; and TOFIDENCE, a tocilizumab biosimilar referencing ACTEMRA. It offers RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, and biosimilars. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; and Sage Therapeutics, Inc., as well as collaborations with Fujirebio to identify and develop biomarkers for tau pathology in the brain and Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Employees
7605
Market
Argentina

Compare BIIBm to Peers and Sector

Metrics to compare
BIIBm
Peers
Sector
Relationship
P/E Ratio
13.2x−3.2x−0.5x
PEG Ratio
0.500.010.00
Price/Book
1.1x1.8x2.6x
Price / LTM Sales
2.0x3.4x3.1x
Upside (Analyst Target)
-97.7%48.3%
Fair Value Upside
Unlock−8.6%7.6%Unlock

Earnings

Latest Release
May 01, 2025
EPS / Forecast
1.64 / --
Revenue / Forecast
2.43B / --
EPS Revisions
Last 90 days

People Also Watch

11,100.00
ADGOm
+0.68%
17,175.00
LLYm
0.00%
11,525.00
UNHm
+2.90%
12,525.00
Fm
-0.99%
18,275.00
BNGm
+1.39%

FAQ

What Is the Biogen AR (BIIBm) Stock Price Today?

The Biogen AR stock price today is 12,100.00

What Stock Exchange Does Biogen AR Trade On?

Biogen AR is listed and trades on the Buenos Aires Stock Exchange stock exchange.

What Is the Stock Symbol for Biogen AR?

The stock symbol for Biogen AR is "BIIBm."

What Is the Biogen AR Market Cap?

As of today, Biogen AR market cap is 22.97T.

What Is Biogen AR's Earnings Per Share (TTM)?

The Biogen AR EPS (TTM) is 10.14.

From a Technical Analysis Perspective, Is BIIBm a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Biogen AR Stock Split?

Biogen AR has split 0 times.

How Many Employees Does Biogen AR Have?

Biogen AR has 7605 employees.

What is the current trading status of Biogen AR (BIIBm)?

As of 13 Jun 2025, Biogen AR (BIIBm) is trading at a price of 12,100.00, with a previous close of 12,250.00. The stock has fluctuated within a day range of 12,050.00 to 12,375.00, while its 52-week range spans from 9,930.00 to 28,500.00.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.